Table 2 Summary of findings
Summary of findings | Quality of evidence | ||||||
|---|---|---|---|---|---|---|---|
Intervention1 (Studies2) | Rank | Study event rates (%) | Risk ratio (95% CrI) | Anticipated absolute effects | Overall certainty of evidence | ||
With standard medical therapy3 | With extracorporeal liver support devices4 | Risk with standard medical therapy | Risk difference with extracorporeal liver support devices | ||||
3-month overall survival (follow-up: range 84 days to 91 days) | |||||||
PE (2 RCTs) | 1 | 334/569 (58.7%) | 136/244 (55.7%) | RR 0.74 (0.60 to 0.94) | 59 per 100 | 15 fewer per 100 (from 23 to 4 fewer) | ⨁◯◯◯ Very low |
MARS (2 RCTs) | 2 | 12/17 (70.6%) | RR 0.78 (0.38 to 1.40) | 13 fewer per 100 (from 36 fewer to 23 more) | ⨁◯◯◯ Very low | ||
Prometheus (1 RCT) | 3 | 46/77 (59.7%) | RR 0.97 (0.68 to 1.40) | 2 fewer per 100 (from 19 fewer to 23 more) | ⨁◯◯◯ Very low | ||
ELAD (4 RCTs) | 4 | 78/213 (36.6%) | RR 0.99 (0.76 to 1.30) | 1 fewer per 100 (from 14 fewer to 18 more) | ⨁◯◯◯ Very low | ||
BioLogic-DT (1 RCT) | 5 | 5/5 (100.0%) | RR 1.00 (0.55 to 2.10) | 0 fewer per 100 (from 26 fewer to 65 more) | ⨁◯◯◯ Very low | ||
1 month overall survival (follow-up: range 28 days to 31 days) | |||||||
PE (1 RCT) | 1 | 122/359 (34.0%) | 19/104 (18.3%) | RR 0.51 (0.12 to 2.40) | 34 per 100 | 17 fewer per 100 (from 30 fewer to 48 more) | ⨁⨁⨁◯ Moderate |
MARS (3 RCTs) | 2 | 109/113 (96.5%) | RR 0.60 (0.15 to 1.30) | 14 fewer per 100 (from 29 fewer to 10 more) | ⨁◯◯◯ Very low | ||
MARS + PE (indirect) | 3 | 7/60 (11.7%) | RR 0.60 (0.07 to 3.20) | 14 fewer per 100 (from 32 fewer to 75 more) | ⨁◯◯◯ Very low | ||
Prometheus (1 RCT) | 4 | 29/77 (37.7%) | RR 1.00 (0.25 to 4.30) | 0 fewer per 100 (from 25 fewer to 100 more) | ⨁◯◯◯ Very low | ||
BioLogic-DT (1 RCT) | 6 | 6/10 (60.0%) | RR 1.10 (0.24 to 5.40) | 3 more per 100 (from 26 fewer to 100 more) | ⨁◯◯◯ Very low | ||
ELAD (3 RCTs) | 7 | 26/117 (22.2%) | RR 1.40 (0.56 to 3.60) | 14 more per 100 (from 15 fewer to 88 more) | ⨁◯◯◯ Very low | ||
3-month transplant-free survival (follow-up: range 84 days to 91 days) | |||||||
PE (1 RCT) | 1 | 189/396 (47.7%) | 42/104 (40.4%) | RR 0.77 (0.51 to 1.10) | 41 per 100 | 11 fewer per 100 (from 23 fewer to 5 more) | ⨁⨁⨁◯ Moderate |
Prometheus (1 RCT) | 2 | 52/77 (67.5%) | RR 0.96 (0.67 to 1.40) | 2 fewer per 100 (from 16 fewer to 19 more) | ⨁◯◯◯ Very low | ||
ELAD (4 RCTs) | 4 | 76/217 (35.0%) | RR 1.00 (0.78 to 1.40) | 0 fewer per 100 (from 11 fewer to 19 more) | ⨁◯◯◯ VERY LOW | ||
MARS (1 RCT) | 5 | 7/8 (87.5%) | RR 1.10 (0.61 to 2.10) | 5 more per 100 (from 19 fewer to 53 more) | ⨁◯◯◯ Very low | ||
1-month transplant-free survival (follow-up: range 28 days to 31 days) | |||||||
ELAD (2 RCTs) | 1 | 109/264 (41.3%) | 14/43 (32.6%) | RR 0.47 (0.13 to 1.20) | 41 per 100 | 22 fewer per 100 (from 36 fewer to 8 more) | ⨁◯◯◯ Very low |
PE (1 RCT) | 2 | 47/104 (45.2%) | RR 0.52 (0.21 to 1.20) | 20 fewer per 100 (from 33 fewer to 8 more) | ⨁⨁⨁◯ Moderate | ||
MARS (3 RCTs) | 3 | 60/122 (49.2%) | RR 0.96 (0.50 to 1.50) | 2 fewer per 100 (from 21 fewer to 21 more) | ⨁◯◯◯ Very low | ||